Results 181 to 190 of about 3,222 (233)
Some of the next articles are maybe not open access.
Novel Platelet Antiaggregating Substances
Biochemical and Biophysical Research Communications, 2001We describe herein a novel action of four stable analogs of the hepoxilins. These analogs inhibit to different degrees, the aggregation of washed human platelets evoked by collagen. One of the analogs, PBT-3, is particularly effective with an IC(50) = 8 x 10(-7) M.
D, Reynaud +3 more
openaire +2 more sources
Platelet Antiaggregants in Stroke Prevention
Neurologic Clinics, 2013Antiplatelet agents are one of the main interventions for recurrent ischemic stroke prevention. Their time of use, dosage, and combination of therapy have different effects in terms of stroke risk reduction and adverse effects. This review provides an evidence-based update of the latest on antiplatelet therapy for stroke prevention.
Sarkis G, Morales Vidal, Sean, Ruland
openaire +2 more sources
Endoscopic Resection of Bladder Cancer in Patients Receiving Double Platelet Antiaggregant Therapy
Background: Approximately 5% of patients who have undergone coronary artery stenting require noncardiac surgery within a year of their cardiac intervention. European cardiological guidelines and recommendations from the U.S.
Giorgio Bozzini +2 more
exaly +2 more sources
Anticoagulation and antiaggregation in pediatrics
Therapeutische Umschau, 2003Das Hämostasesystem mit primärer und sekundärer Hämostase sowie die Fibrinolyse unterliegen einem Entwicklungsprozess, der zu qualitativen und quantitativen Unterschieden zwischen Kindern und Erwachsenen führt, aber auch zu verschiedenen Eigenschaften innerhalb der einzelnen Altersgruppen des Kindesalters.
openaire +2 more sources
Platelet antiaggregate activity
American Heart Journal, 1991Calcium ions act as a second messenger to platelet agonists, with increases in intracellular calcium bringing about changes in shape, aggregation, and release reactions. Changes in platelet function have been reported previously in migraine sufferers and there is evidence that hyperaggregability occurs during a migraine attack. It was decided to assess
openaire +2 more sources
Quinolizidinyl‐benzimidazoles as Platelet‐Antiaggregating Agents
Chemistry & Biodiversity, 2008AbstractTwo series of (±)‐2‐phenyl‐1‐(quinolizidin‐1α‐yl)benzimidazoles, 12A–26A, and (±)‐2‐phenyl‐1‐(quinolizidin‐1β‐yl)benzimidazoles, 12B–26B, were prepared and tested for the inhibition of human platelets aggregation induced by ADP, collagen, and adrenaline. All epimers A, i.e., 12A–26A, were devoid of any activity against the three agonists, while
VAZZANA, IANA +6 more
openaire +3 more sources
Heparin and Antiaggregating Therapy in Unstable Angina
Haemostasis, 2009Heparin and antiaggregating therapy represent an effective treatment of unstable angina. Aspirin is able to prevent myocardial infarction and death in patients with unstable angina, but is not able to control myocardial ischemia. On the contrary, heparin administered by continuous intravenous infusion (about 1,000 U/h) controls myocardial ischemia by ...
NERI SERNERI, GIAN GASTONE +3 more
openaire +3 more sources
Anticoagulative and antiaggregate therapy of glomerulonephritis
International Urology and Nephrology, 1988If fibrinogen is present in renal biopsy specimens with glomerulonephritis, anticoagulants, antiaggregants and immunomodulation therapy are successful.
openaire +2 more sources
Abciximab: A New Antiaggregant Used in Angioplasty
Annals of Pharmacotherapy, 1996OBJECTIVE: To review the scientific literature on the pharmacology and clinical uses of abciximab. DATA SOURCES: MEDLINE, Index Medicus, and bibliographic literature searches of English-language articles pertaining to abciximab, 7E3 ...
T B, Genetta, V F, Mauro
openaire +2 more sources
Therapeutische Umschau. Revue therapeutique, 2003
Many randomized trials have shown aspirin as an effective antiplatelet drug for the secondary prevention of cardiovascular events. The NNT (number needed to treat) to prevent 1 vascular event is about 25. The NNH (number needed to harm) inducing one cerebral bleeding is about 1'000, to provoke one severe extracerebral bleeding about 100-200.
A, Eichenberger, L, Pontiggia, J H, Beer
openaire +1 more source
Many randomized trials have shown aspirin as an effective antiplatelet drug for the secondary prevention of cardiovascular events. The NNT (number needed to treat) to prevent 1 vascular event is about 25. The NNH (number needed to harm) inducing one cerebral bleeding is about 1'000, to provoke one severe extracerebral bleeding about 100-200.
A, Eichenberger, L, Pontiggia, J H, Beer
openaire +1 more source

